3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
13
Carcinoma, Renal Cell
6
Tuberous Sclerosis
5
Neoplasm Metastasis
5
Hodgkin Disease
5
Glioblastoma
5
Colorectal Neoplasms
5
Central Nervous System Neoplasms
5
Waldenstrom Macroglobulinemia
4
Stomach Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Pancreatic Neoplasms
4
Lymphoma, Mantle-Cell
4
Head and Neck Neoplasms
4
Gliosarcoma
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Sezary Syndrome
3
Recurrence
3
Prostatic Neoplasms
3
Neoplasms
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Kidney Neoplasms
3
Interventions
cemiplimab
1
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Cutaneous Squamous Cell Carcinoma
×
Everolimus
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts